Yahoo Finance3d
Arrowhead and Sarepta link for rare genetic disease treatments
Arrowhead Pharmaceuticals has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics to develop treatments for rare genetic diseases. Arrowhead will receive an $825m ...
STAT4d
Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases
Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases in the muscle, nervous system ...
Yahoo Finance3d
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
These programs are being developed against a broad range of genetic diseases in muscle, central nervous system (CNS) and rare pulmonary disorders. Each of the four clinical programs is currently being ...
Investing12d
Arrowhead seeks FDA nod for rare disease drug
PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for plozasiran, a treatment ...
Investing12d
Arrowhead seeks FDA nod for rare disease drug
PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for plozasiran, a treatment designed ...
FiercePharma25d
Arrowhead targets rare disease patients, pushing message that hope is on the horizon
Arrowhead Pharmaceuticals has begun laying the groundwork for its entry into a rare disease market, kicking off an awareness campaign focused on the unmet need its drug candidate is positioned to ...